Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Insight Molecular Diagnostics' Prepaid Assets rose 9760.77% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 9760.77%. This contributed to the annual value of $821000.0 for FY2024, which is 2768.27% up from last year.
  • Insight Molecular Diagnostics' Prepaid Assets amounted to $1.2 million in Q3 2025, which was up 9760.77% from $1.3 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Prepaid Assets' 5-year high stood at $2.3 million during Q1 2021, with a 5-year trough of $595000.0 in Q2 2024.
  • Its 5-year average for Prepaid Assets is $1.2 million, with a median of $1.2 million in 2023.
  • In the last 5 years, Insight Molecular Diagnostics' Prepaid Assets soared by 14092.34% in 2021 and then tumbled by 6908.92% in 2023.
  • Insight Molecular Diagnostics' Prepaid Assets (Quarter) stood at $901000.0 in 2021, then increased by 8.44% to $977000.0 in 2022, then plummeted by 34.19% to $643000.0 in 2023, then grew by 27.68% to $821000.0 in 2024, then skyrocketed by 50.91% to $1.2 million in 2025.
  • Its Prepaid Assets stands at $1.2 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.2 million for Q1 2025.